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Loss of p21WAFIIcIPI expression correlates with disease
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Summary Previous studies have shown that tumour-suppressor genes play an important role in the progression of solid tumours. Recently,
the p21WAF1/C1P1 tumour-suppressor protein has been reported to work as a critical downstream effector of p53 and a potent inhibitor of cyclin-
dependent kinases. Thus, the p21WAF1/cIPl gene is thought to play a central role in tumour suppression. In this study we investigated p21
protein expression in gastric carcinomas. A total of 172 primary gastric carcinoma specimens were immunohistochemically stained for p21
protein expression. Correlations between p21 expression and clinicopathological features were examined. Loss of p21 expression was
observed in 104 of 172 tumour tissues (60.4%), and the frequency of p21 loss increased as the stage progressed. Expression of p21 in the
primary tumour was frequently lost in patients with either lymph node, liver or peritoneal metastases as compared with patients without
metastases. In patients with p21-negative tumours, the risk of recurrence following curative surgery was significantly higher, and the
prognosis was significantly poorer than in patients with p21-positive tumours. Loss of p21 expression in primary gastric carcinoma correlates
with disease progression. The status of p21 gene expression may have prognostic value in this disease.
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Thep21 protein, auniversal cycin-dependentkinase (CDK) inhibitor,
was first identified as cyclin-dependent kinase interacting protein 1
(CIP1) from studies trying to characterize upstream regulating factors
ofCDK (Harper et al, 1993). The gene is located on chromosome 6p
(El-Deiry et al, 1993; Harperet al, 1993; Dulic etal, 1994; Nodaetal,
1994). The p21 protein has been reported not only to inhibit CDK
function, but also to interact with proliferating cell nuclear antigen
(PCNA) (Xiong et al, 1993), bcl-2 (Upadhyay et al, 1995) and c-myc
(Hermeking etal, 1995), toinhibitDNAreplication (Dulic etal, 1994;
Flores-Rozas et al, 1994; Li et al, 1994) and to block cell cycle
progression. Taken together, these data suggest that the p21 protein
plays a central role in cell cycle regulation. Mutations in the p21 gene
have been demonstrated in prostate cancer (Xiang et al, 1995), and
abnormal p21 expression has been found in brain tumour (Jung et al,
1995) and colon cancer (El-Deiry et al, 1995), suggesting an involve-
ment ofthis gene in malignancies.
p21 was also cloned as wild-type p53 activated ftagment-1
(WAFI) from studies looking for downstream effectors of p53
(El-Deiry et al, 1993). The p53 protein can induce p21 expression
by binding to an upstream regulatory site of the p21 gene. This
induction requires wild-type p53 activity, suggesting that p21 is a
critical downstream effector ofp53. Thus, it is reasonable to inves-
tigate the involvement of p53 function in cell cycle regulation by
examining p21 protein expression. The p53 gene is an important
tumour suppressor, and the correlation between its overexpression
and tumour progression has been shown in gastric carcinoma
(Martin et al, 1992; Joypaul et al, 1994; Gabbert et al, 1995).
However, the mechanism showing how the p53 gene is involved
has not yet been identified.
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In this study we examined p21 protein expression by immuno-
histochemistry in gastric carcinoma and demonstrated a correla-
tion between loss of p21 expression and disease progression. We
also found that the absence of p21 protein expression indicated a
poorer prognosis.
MATERIALS AND METHODS
Clinical materials
A total of 172 operative specimens from patients with primary
gastric adenocarcinoma was examined. This population included
110 men and 62 women. Their ages ranged between 28 and 82
years with an average of 59.5 years. No patients had received
chemotherapy orradiation therapy before surgery. Throughout this
report the General Rules for Gastric Cancer Study (Japanese
Research Society for Gastric Cancer, 1981) were used for the
clinicopathological classification, with one exception: tumours
were divided into two histological subgroups - a differentiated
type, which consisted of papillary and tubular adenocarcinomas,
and an undifferentiated type, which included poorly differentiated
adenocarcinoma, signet ring cell carcinoma and mucinous adeno-
carcinoma. All patients underwent gastrectomy. Curative resec-
tions were performed in 133 patients, and 39 patients underwent
non-curative surgical procedures.
Immunohistochemical techniques
Immunohistochemical staining was used to study p21 protein
expression in tissues. Formalin-fixed, paraffin-embedded tissue
blocks that included both normal mucosa and carcinoma were
obtained from each patient. Immunohistochemistry was performed
as previously described (Maeda et al, 1995). Briefly, sections were
dewaxed and microwave pretreated (three times for 5 min at
500 W in 10 mm citrate buffer), followed by incubation with 0.3%
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hydrogen peroxide in methanol for 30 min. After blocking with
10% normal rabbit serum, mouse monoclonal antibody against p21
protein EAIO (5 gg ml-1) (Oncogene Science, Cambridge, MA,
USA), was reacted with tissue sections (room temperature for 2 h)
followed by three washes with phosphate-buffered saline. The
sections were incubated with biotinylated rabbit anti-mouse IgG,
then reacted with streptavidin-biotin peroxidase reagent (Histofine
Kit, Nichirei, Tokyo, Japan). Finally, the chromogen, diamino-
benzidine, and 1% hydrogen peroxidase were applied. Slides were
counterstained with haematoxylin. Normal mouse IgG was substi-
tuted forprimary antibody as the negative control.
The sections were assessed independently by two investigators
without knowledge of the patient's clinical outcome. Nuclear
staining of cells was considered positive evidence of p21 expres-
sion. No cytoplasmic staining was seen in this study.
Statistics
The chi-square test was used to define statistical difference.
Survival curves for patients were calculated using the
Kaplan-Meier method and analysed by the generalized Wilcoxon
test. Statistical significance was defined as P < 0.05.
RESULTS
Positive staining for the p21 protein was observed in the majority
of crypts in normal gastric epithelium. In 68 of 172 (39.6%)
tumours, the p21 protein was also detected in more than 5% ofthe
cancer cells, and these tumours were designated p21-positive
(Figure IA). Most of the p21-positive tumours demonstrated
staining in greater than 50% ofcancercells, whereas tumours with
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Figure 1 Immunohistochemistry of gastric carcinoma tissues. (A) p21-expressing tumours demonstrated staining in more than 5% of cancer cells. In the
majority of cases more than 50% of the cancer cells stained. (B) In p21-negative tumours, less than 5% of the cancer cells stained
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Table 1 p21 expression status in gastric carcinomas and clinicopathological
features
n p21-negative tumour (%)
Histological type
Differentiated
Undifferentiated
Depth of invasion
m
sm
mp
ss
se
Si
Lymphatic invasion
Negative
Positive
Venous invasion
Negative
Positive
68 34/68 (50)
104 70/104 (67.3)
34
48
8
7
53
22
11/34 (32.4)
18/48 (37.5)
5/8 (62.5)
5/7 (71.4)
44/53 (83)
21/22 (95.5)
86
86
43 (50)
61 (70.9)
103
69
53 (51.5)
51 (73.9)
(0)
100-
Pvalue
< 0.05
< 0.001 a
< 0.01
< 0.01
80 _-
-1
0
E
a)
CZ
a)
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Q.
I i
60 -
40 _-
20 _
II III IV Stage
Figure 2 The frequency of P21-negative tumours increased with higher
histological stage. *P < 0.001. **P < 0.005
m, mucosal neoplastic involvement; sm, submucosal neoplastic involvement:
mp, muscle layer neoplastic involvement; ss, subserosal neoplastic
involvement; se, serosal neoplastic involvement; si, neoplastic involvement
with directly infiltrating other organs beyond serosa.
aStatistical significance was determined when compared (m, sm) vs (mp or
beyond), or (ss or less) vs (se or beyond).
Table 2 Correlation between p21 expression and metastasis
p21 lost tumour (%) P value
Lymph node metastasis
Negative 25/73 (34.2) < 0.0001
Positive 79/99 (79.8)
Liver metastasis
Negative 89/155 (57.4) < 0.05
Positive 15/17 (88.2)
Peritoneal metastasis
Negative 65/128 (50.8) < 0.001
Positive 39/44 (88.6)
Table 3 Correlation between p21 expression and recurrence after curative
resection
Recurrence p21 lost tumour (%) Pvalue
Negative 42/92 (45.7) <0.0001
Positive 36/41 (87.8)
5-50%/c of p2 l-positive cells were found in exceptional cases only.
Stainine was detectable in <5% of cancer cells in 104 of 172
(60.4%) tumours (Figure IB). Thus, p21 expression could be
clear-ly def-ined in our population oftumllours.
Possible correlationis between p21 status and clinicopatholog-
ical features were examined (Table 1). There was no association
betweeni p2 1 status and tumour location. A significant association
was found between histological type and p21 status. There was
also an association between the loss ot p21 expression anid the
depth of tumour invasion. In tumours without muscle invasion (In,
sin). classified as ear-ly cancers, p21-negative tumours were found
in 29 of 82 cases (35.4%). However. 75 of 90 cases (83.3%) with
100
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CZ
> 40
20 -
p21 - positive tumour
P< 0.05
p21 - negative tumourL
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Figure 3 Kaplan-Meier plot of survival rate after curative resection
muscle invasion or beyond (mip, ss, se or si) were p21-neg.ative,
and this frequency was significantly higher than in the early
cancers. Similar significance was found when tumours were
divided with serosal invasion status. p21 loss was significantly
more frequent in tumours with venous and lymphatic invasion
(Table I).
Of the 172 patients, lymph node, liver and peritoneal metastasis
were found in 99, 17 and 44 patients respectively. p21 expressioni
was more frequently lost in tumours from patients with metastases
(Table 2). There was also a strong correlation between p21 loss
and increasing tumour grade (Figure 2).
We selected 133 patients who underwenlt curative operation and
examined their outcome following surgery. The survival rate of
patients with p21-negative tumours was significantly lower thani
that of patients with p21-positive tumours (Figure 3). The rate of
p21 lost tumour in the patients with recurrence was 87.8% (36 out
of 41 ). This was significantly higher than that of patients without
recurrence (Table 3).
DISCUSSION
In this situdy we comiipar-ed the clinicopathological features of
patients with p2 1 -positive and -negYative primary tumours.
Although there was no relationship between p21 expression and
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tumour location, there was a correlation with histological type. A
strong association with disease progression was also clearly
demonstrated. Moreover, the majority of the patients with p21-
negative tumours had metastatic lesions, suggesting a possible
involvement ofp21 loss in cancer metastasis. Finally, the status of
p21 protein expression also appeared to have prognostic value.
Our demonstration of differences in p21 expression between
histological types is similar to the findings with p53, an inducer
of p21 (Gabbert et al, 1995). These data reflect the apparently
different molecular characteristics ofthe two types. Other investi-
gators have also shown that p21 loss correlates positively with the
depth of cancer invasion and also stage progression in primary
prostate cancer (Gao et al, 1995). Similar abnormalities have been
reported in studies of other cell cycle-regulating factors such as
p53 (Joypaul et al, 1994), Rb (Constancia et al, 1994), cyclins
(Tahara E, 1994) and PCNA (Maeda et al, 1994). Our study and
others suggest that cell cycle deregulation is an important factor in
gastric cancer progression.
In this study metastases were more frequent in cases with p21-
negative primary tumours (79.8% in those with lymph node metas-
tases, 88.2% in those with liver metastases and 88.6% in those
with peritoneal spread). These results strongly suggest that p21
loss is involved in the process of metastasis. However, it is
possible that p21 loss is secondary to disease progression, as
cancer cells with high proliferative activity may have a higher
potential for metastasis than those with low proliferative activity
(Maeda et al, 1996).
We observed a better prognosis in patients with p21-positive
tumours than with p21-negative tumours. To avoid the influence of
initial disease stage on outcome, we selected only patients who
had a curative operation. One explanation for this result may lie in
studies that relate p53 function and treatment resistance. Several
reports have suggested that loss of p53 function may lead to
chemotherapy (Fan et al, 1994) and radiation therapy resistance
(O'Connor et al, 1993). Furthermore, some clinical studies have
reported that tumour cell lines lacking p53 function are resistant to
multiple chemotherapeutic agents and radiation therapy (Hawkins
et al, 1996). Thus, tumours with p21 expression, indicating normal
p53 protein function, may have higher sensitivity to adjuvant
chemotherapy and therefore a better prognosis.
This retrospective study demonstrated that p21 expression
strongly correlated with disease progression. If our findings are
confirmed in a prospective fashion, p21 expression may be of
considerable clinical importance in stratifying patients for addi-
tional therapy following operation.
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